Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response

Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response

Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor prognosis. Gemcitabine is the first-line therapy for PDAC, but gemcitabine resistance is a major impediment to achieving satisfactory clinical outcomes. This study investigated whether methylglyoxal (MG), an oncometabolite spontane...

Full description

Bibliographic Details
Main Authors: Rebekah Crake, Imène Gasmi, Jordan Dehaye, Fanny Lardinois, Raphaël Peiffer, Naïma Maloujahmoum, Ferman Agirman, Benjamin Koopmansch, Nicky D’Haene, Oier Azurmendi Senar, Tatjana Arsenijevic, Frédéric Lambert, Olivier Peulen, Jean-Luc Van Laethem, Akeila Bellahcène
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Cells
Subjects:
oncometabolite
methylglyoxal
glycolysis
therapy resistance
gemcitabine
metformin
Online Access:https://www.mdpi.com/2073-4409/12/10/1414

Internet

https://www.mdpi.com/2073-4409/12/10/1414

Similar Items